News

Company has completed $1.6M of $2.5M private placement to support continuing development and expansion

Lexington, KY, August 17, 2016 -- Nexeon MedSystems, Inc. (“Nexeon” or “the Company”) announced today that on July 6 it filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC).  Nexeon will continue to manage its existing portfolio of medtech intellectual property from development to commercialization.

“Filing the Form 10 [Registration Statement] marks an important milestone in our strategic efforts to capitalize on future growth opportunities,” said CEO Will Rosellini.  “We believe that coupling our scientific programs with the financial transparency afforded to a public trading and SEC reporting company will establish Nexeon as an industry favorite to follow and invest.”

The Company’s leading medtech program is a carbon-nantobue, micro-perforated catheter balloon for intravascular drug delivery systems.  Nexeon has developed an innovation pipeline process that leverages the review system of various non-dilutive grant programs, both in the U.S. and international, to enhance protocols, exact inflection points, and derisk planned clinical programs.  A portion of the proceeds of the private placement will used to support ongoing clinical trials of 510k devices that are not currently supported by non-dilutive funding programs.  

Nexeon’s Form 10 Registration Statement includes financial information related to Company business, details of the management team, a competitive analysis, and corporate strategies.  Audited financial statements are also included for fiscal years ending on Dec 31, 2014, and 2015, and interim financial statements for the period of Jan 1-Jun 30, 2016.  On Aug 16, the Company filed its first amended Form 10 in response to the initial review by the SEC. A copy of the Form 10 can be found in the Investor Section of Nexeon’s website at www.nexeonmed.com/investors and on the SEC’s website at www.sec.gov. A copy of the Company’s current Private Placement Memorandum can be obtained via direct contact with the Company at [email protected].

About Nexeon MedSystems: Nexeon MedSystems was founded in 2004 by super-innovator, interventional cardiologist Dr. Mark C. Bates of West Virginia.  Dr. Bates is attributed to innovation of over 60+ US and international patents, and over the past decade, Nexeon has experienced several exits and product launches.  In early 2016, Rosellini Scientific, a medtech incubator, contributed assets to Nexeon and brought with it a pipeline of preclinical and clinical projects supported with non-dilutive funding as well as holdings in seven existing medtech startup companies.  Nexeon has since moved its corporate headquarters to Lexington, Kentucky, and plans to continue the development and manufacturing of its portfolio of medical device products. For more information, visit www.nexeonmed.com

Forward-Looking and Cautionary Statements: Statements in this press release that are not strictly historical may be “forward-looking” statements, which involve risks and uncertainties, and Nexeon undertakes no obligation to update any such statements to reflect later developments. These risks and uncertainties include Nexeon’s ability to successfully complete on the terms and conditions contemplated, and the financial impact of, its strategic portfolio repositioning actions, as well as economic and currency conditions, market demand, pricing, protection of intellectual property, and competitive and technological factors, among others, as set forth in Nexeon’s subsequent reports filed with the SEC.